Robin Steigerwald
26Patents
1h-index
18Co-inventors
50Inventor score
Filing activity: Nov 20, 2009 → Oct 11, 2021
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9463238B2 | Recombinant poxvirus vector comprising tetanus toxin fragment C | Human Necessities | 2 | Active |
| US10072274B2 | Vector comprising multiple homologous nucleotide sequences | Chemistry; Metallurgy | 1 | Active |
| US10881725B2 | Recombinant modified vaccinia virus Ankara (MVA) equine encephalitis virus vaccine | Chemistry; Metallurgy | 1 | Active |
| US9828414B2 | Pr13.5 promoter for robust T-cell and antibody responses | Chemistry; Metallurgy | 1 | Active |
| US10561722B2 | Methods and compositions for enhancing immune responses | Chemistry; Metallurgy | 1 | Active |
| US11338030B2 | Multivalent recombinant modified vaccinia virus ankara (MVA) vector encoding filovirus immunogens | Emerging Cross-Sectional Technologies | 0 | Active |
| US10561721B2 | Methods and compositions for inducing protective immunity against filovirus infection | Emerging Cross-Sectional Technologies | 0 | Active |
| US11918639B2 | Methods and compositions for inducing protective immunity against filovirus infection | Emerging Cross-Sectional Technologies | 0 | Active |
| US11571471B2 | Recombinant modified vaccinia virus ankara (MVA) equine encephalitis virus vaccine | Chemistry; Metallurgy | 0 | Active |
| US11028130B2 | PR13.5 promoter for robust T-cell and antibody responses | Chemistry; Metallurgy | 0 | Active |
| US9480738B2 | Recombinant modified vaccinia virus ankara (MVA) respiratory syncytial virus (RSV) vaccine | Chemistry; Metallurgy | 0 | Active |
| US10576141B2 | Recombinant modified vaccinia virus Ankara (MVA) multivalent filovirus immunogenic compositions and methods of use | Emerging Cross-Sectional Technologies | 0 | Active |
| US9540660B2 | Vector comprising multiple homologous nucleotide sequences | Chemistry; Metallurgy | 0 | Active |
| US10532094B2 | Recombinant modified vaccinia virus ankara (MVA) respiratory syncytial virus (RSV) vaccine | Chemistry; Metallurgy | 0 | Active |
| US11225673B2 | Stable recombinant MVA vectors comprising modified RSV genes with reduced intramolecular recombinatorial activity | Chemistry; Metallurgy | 0 | Active |
| US8999637B2 | Vector comprising multiple homologous nucleotide sequences | Chemistry; Metallurgy | 0 | Active |
| US8772023B2 | Promoters for recombinant viral expression | Chemistry; Metallurgy | 0 | Active |
| US11173201B2 | Methods and compositions for inducing protective immunity against filovirus infection | Emerging Cross-Sectional Technologies | 0 | Active |
| US10946089B2 | Recombinant modified vaccinia virus ankara (MVA) respiratory syncytial virus (RSV) vaccine | Chemistry; Metallurgy | 0 | Active |
| US10111946B2 | Poxviral vectors for low antibody response after a first priming immunization | Chemistry; Metallurgy | 0 | Active |
| US9717787B2 | Recombinant modified vaccinia virus ankara (MVA) respiratory syncytial virus (RSV) vaccine | Chemistry; Metallurgy | 0 | Active |
| US10124058B2 | Recombinant modified vaccinia virus Ankara (MVA) Respiratory Syncytial Virus (RSV) vaccine | Chemistry; Metallurgy | 0 | Active |
| US9173933B2 | Recombinant modified vaccinia virus Ankara influenza vaccine | Chemistry; Metallurgy | 0 | Active |
| US10653766B2 | Use of oil and water emulsions for increasing B cell responses with modified Vaccinia Ankara virus | Emerging Cross-Sectional Technologies | 0 | Active |
| US11103570B2 | Recombinant modified vaccinia virus Ankara (MVA) foot and mouth disease virus (FMDV) vaccine | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.